| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We analyzed whether enforced E-selectin ligand expression on murine mesenchymal stem cells (MSCs) could impact their effect in reversing autoimmune disease model mice. Although murine MSCs natively do not express the E-selectin-binding determinant sialyl Lewis x (sLex), we found that fucosyltransferase-mediated alpha (1,3)-exofucosylation of murine MSCs resulted in sLex display uniquely on cell surface CD44 thereby creating hematopoietic cell E-/L-selectin ligand (HCELL), the E-selectin-binding glycoform of CD44. The findings provide evidence that glycan engineering to enforce HCELL expression boosts trafficking of infused MSCs to inflamed site and substantially improves their efficacy in reversing autoimmune disease.
|
